UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$438M |
| 2 |
Lockheed Martin
LMT
|
+$402M |
| 3 |
TAL Education Group
TAL
|
+$294M |
| 4 |
Microsoft
MSFT
|
+$269M |
| 5 |
Wells Fargo
WFC
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mastercard
MA
|
+$384M |
| 2 |
Adobe
ADBE
|
+$372M |
| 3 |
Veeva Systems
VEEV
|
+$342M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$289M |
| 5 |
Global Payments
GPN
|
+$287M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.1% |
| 2 | Consumer Discretionary | 13.57% |
| 3 | Healthcare | 12.46% |
| 4 | Financials | 11.55% |
| 5 | Communication Services | 9.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCPC
1301
Balchem Corp
BCPC
$5.65B
| $4.43M | ﹤0.01% |
38,446
+2,948
| +8% | +$311K |
|
1302
Avient
AVNT
$4.19B
| $4.43M | ﹤0.01% |
109,963
+4,574
| +4% | +$161K |
|
|
MZTI
1303
The Marzetti Company
MZTI
$3.13B
| $4.42M | ﹤0.01% |
24,079
+973
| +4% | +$170K |
|
|
THS
1304
DELISTED
Treehouse Foods
THS
| $4.38M | ﹤0.01% |
103,012
+12,917
| +14% | +$525K |
|
1305
Dianthus Therapeutics
DNTH
$6.25B
| $4.37M | ﹤0.01% |
34,854
-3,244
| -9% | -$368K |
|
1306
PennyMac Financial
PFSI
$3.94B
| $4.36M | ﹤0.01% |
66,386
-1,590
| -2% | -$94.6K |
|
1307
Hyatt Hotels
H
$16B
| $4.35M | ﹤0.01% |
58,651
+38,833
| +196% | +$2.53M |
|
1308
The Ensign Group
ENSG
$10.7B
| $4.35M | ﹤0.01% |
59,701
+676
| +1% | +$44.8K |
|
1309
Gold Fields
GFI
$36.8B
| $4.35M | ﹤0.01% |
468,979
+3,400
| +0.7% | +$35.9K |
|
1310
Lazard
LAZ
$4.16B
| $4.32M | ﹤0.01% |
102,158
+23,147
| +29% | +$874K |
|
1311
Nektar Therapeutics
NKTR
$2.53B
| $4.32M | ﹤0.01% |
16,940
+2,349
| +16% | +$607K |
|
1312
Trupanion
TRUP
$1.27B
| $4.32M | ﹤0.01% |
36,060
+5,369
| +17% | +$507K |
|
|
TMHC
1313
DELISTED
Taylor Morrison
TMHC
| $4.3M | ﹤0.01% |
167,514
+1,227
| +0.7% | +$31.3K |
|
1314
WillScot Mobile Mini Holdings
WSC
$4.18B
| $4.28M | ﹤0.01% |
184,872
+51,172
| +38% | +$1.03M |
|
|
STMP
1315
DELISTED
Stamps.com, Inc.
STMP
| $4.28M | ﹤0.01% |
21,824
+2,196
| +11% | +$482K |
|
1316
Synaptics
SYNA
$4.09B
| $4.28M | ﹤0.01% |
44,397
+614
| +1% | +$50K |
|
|
BBBY
1317
DELISTED
Bed Bath & Beyond Inc
BBBY
| $4.25M | ﹤0.01% |
239,433
-6,527
| -3% | -$135K |
|
|
BHVN
1318
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4.25M | ﹤0.01% |
49,585
+4,627
| +10% | +$392K |
|
1319
Dana Inc
DAN
$3.21B
| $4.22M | ﹤0.01% |
216,360
+9,544
| +5% | +$160K |
|
1320
TripAdvisor
TRIP
$1.26B
| $4.22M | ﹤0.01% |
146,651
-600,867
| -80% | -$14.5M |
|
1321
Cardlytics
CDLX
$22.4M
| $4.21M | ﹤0.01% |
2,950
+709
| +32% | +$756K |
|
1322
Kirby Corp
KEX
$7B
| $4.21M | ﹤0.01% |
81,183
+33,277
| +69% | +$1.52M |
|
1323
Bankunited
BKU
$3.34B
| $4.2M | ﹤0.01% |
120,849
+28
| +0% | +$799 |
|
|
MDLA
1324
DELISTED
Medallia, Inc.
MDLA
| $4.18M | ﹤0.01% |
125,852
+18,899
| +18% | +$603K |
|
1325
Cerence
CRNC
$403M
| $4.17M | ﹤0.01% |
41,524
+14,218
| +52% | +$1.06M |
|
Similar funds
UBS AM's Q4 2020 Portfolio in Review
As of Q4 2020, UBS AM held 2,632 positions worth $213B, up 15% from $186B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
UBS AM's Q4 2020 filing shows 139 new, 1,393 increased, 625 reduced and 83 closed positions. Its largest new stake was Maravai LifeSciences: 3,763,012 shares worth $106M. The largest sale was Mastercard, an estimated $384M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- UBS AM's largest Q4 2020 buy was Maravai LifeSciences: 3,763,012 shares worth $106M.
- UBS AM added most to Apple in Q4 2020, an estimated $438M increase.
- UBS AM's biggest Q4 2020 reduction was Mastercard, cutting an estimated $384M.
- UBS AM fully exited State Street Technology Select Sector SPDR ETF in Q4 2020, selling an estimated $115M.
- UBS AM's ten largest holdings make up 23% of its $213B portfolio in Q4 2020.
- UBS AM opened 139 new positions and closed 83 in Q4 2020.
- UBS AM's portfolio value rose 15% quarter-over-quarter to $213B.
Based on UBS AM's 13F filing for Q4 2020, filed 17 Feb 2021.